

NICE technology appraisals for medicines

Formulary adherence checklist

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals	94
CCG commissioned	17
Non-CCG commissioned	51
Not applicable	27
CCG commissioned and approved	17 (100%)
Average days to compliance	30

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Acalabrutinib for treating chronic lymphocytic leukaemia [TA689]	Recommended	21/04/2021	TA	20/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Teduglutide for treating short bowel syndrome (terminated appraisal) [TA690]	Terminated appraisal	21/04/2021	TA					n/a	Link added to formulary
Avelumab for untreated metastatic Merkel cell carcinoma [TA691]	Recommended	21/04/2021	TA	20/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA692]	Not recommended	28/04/2021	TA					n/a	Link added to formulary Replaces TA519
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [TA693]	Recommended	28/04/2021	TA	27/07/2021	Non-CCG			This technology is commissioned by NHS England (CDF). Providers are NHS hospital trusts.	Link added to formulary
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [TA694]	Recommended	28/04/2021	TA	27/07/2021	CCG	26/05/2021	28	This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts and GPs.	Pan Mersey APC green statement
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma [TA695]	Recommended	28/04/2021	TA	27/07/2021	Non-CCG			This technology is commissioned by NHS England.	Link added to formulary
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [TA696]	Not recommended	12/05/2021	TA					n/a	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban [TA697]	Recommended	12/05/2021	TA	10/08/2021	CCG	26/05/2021	14	This technology is commissioned by integrated care systems (ICSs)/ clinical commissioning groups (CCGs). Providers are NHS hospital trusts	Pan Mersey APC red statement
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [TA698]	Recommended	19/05/2021	TA	17/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ofatumumab for treating relapsing multiple sclerosis [TA699]	Recommended	19/05/2021	TA	17/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) [TA700]	Terminated appraisal	19/05/2021	TA					n/a	Link added to formulary
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) [TA701]	Terminated appraisal	19/05/2021	TA					n/a	Link added to formulary
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) [TA702]	Terminated appraisal	26/05/2021	TA					n/a	Link added to formulary
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) [TA703]	Terminated appraisal	26/05/2021	TA					n/a	Link added to formulary
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [TA704]	Recommended	26/05/2021	TA	24/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [TA705]	Recommended	02/06/2021	TA	31/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ozanimod for treating relapsing-remitting multiple sclerosis [TA706]	Not recommended	09/06/2021	TA					n/a	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer [TA707]	Recommended	15/06/2021	TA	13/09/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis [TA708]	Recommended	23/06/2021	TA	21/09/2021	CCG	28/07/2021	35	This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [TA709]	Recommended	23/06/2021	TA	21/09/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ravulizumab for treating atypical haemolytic uraemic syndrome [TA710]	Recommended	23/06/2021	TA	21/09/2021	Non-CCG			This technology is commissioned by NHS England. Providers are tertiary care providers.	Link added to formulary
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA711]	Recommended	30/06/2021	TA	28/09/2021	CCG	28/07/2021	28	This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Enzalutamide for treating hormone-sensitive metastatic prostate cancer [TA712]	Recommended	07/07/2021	TA	05/10/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy [TA713]	Recommended	07/07/2021	TA	05/10/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) [TA714]	Terminated appraisal	14/07/2021	TA					n/a	Link added to formulary
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed [TA715]	Recommended	14/07/2021	TA	12/10/2021	CCG	28/07/2021	14	These technologies are commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [TA716]	Recommended	28/07/2021	TA	26/10/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS trust hospitals.	Link added to formulary
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) [TA717]	Terminated appraisal	21/07/2021	TA					n/a	Link added to formulary
Ixekizumab for treating axial spondyloarthritis [TA718]	Recommended	21/07/2021	TA	19/10/2021	CCG	22/09/2021	63	This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Secukinumab for treating non-radiographic axial spondyloarthritis [TA719]	Recommended	21/07/2021	TA	19/10/2021	CCG	22/09/2021	63	This technology is commissioned by integrated care systems / clinical commissioning groups.	Pan Mersey APC red statement
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [TA720]	Recommended	18/08/2021	TA	16/11/2021	Non-CCG			This technology is commissioned by NHS England and Improvement. Providers are NHS hospital trusts.	Link added to formulary
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer [TA721]	Not recommended	18/08/2021	TA					n/a	Link added to formulary
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [TA722]	Recommended	25/08/2021	TA	23/11/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Bimekizumab for treating moderate to severe plaque psoriasis [TA723]	Recommended	01/09/2021	TA	30/11/2021	CCG	22/09/2021	21	This technology is commissioned by integrated care systems/clinical commissioning groups and strategic transformation partnerships. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer [TA724]	Not recommended	08/09/2021	TA					n/a	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [TA725]	Recommended	15/09/2021	TA	14/12/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA726]	Terminated appraisal	22/09/2021	TA					n/a	Link added to formulary
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA727]	Terminated appraisal	22/09/2021	TA					n/a	Link added to formulary
Midostaurin for treating advanced systemic mastocytosis [TA728]	Recommended	22/09/2021	TA	21/12/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS trust hospitals.	Link added to formulary
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria [TA729]	Recommended	29/09/2021	TA	28/12/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS trust hospitals.	Link added to formulary
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) [TA730]	Terminated appraisal	29/09/2021	TA					n/a	Link added to formulary
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) [TA731]	Terminated appraisal	29/09/2021	TA					n/a	Link added to formulary
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)	Terminated appraisal	06/10/2021	TA					n/a	Link added to formulary
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia	Recommended	06/10/2021	TA	04/01/2022	CCG	27/10/2021	21	The technology is commissioned by integrated care systems or clinical commissioning groups. Providers are primary care services.	Pan Mersey APC green statement
Secukinumab for treating moderate to severe plaque psoriasis in children and young people	Recommended	07/10/2021	TA	05/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Tofacitinib for treating juvenile idiopathic arthritis	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Berotralstat for preventing recurrent attacks of hereditary angioedema	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	Recommended	27/10/2021	TA	25/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer	Recommended	27/10/2021	TA	25/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer	Recommended	28/10/2021	TA	26/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Selpercatinib for treating advanced thyroid cancer with RET alterations [TA742]	Recommended	03/11/2021	TA	01/02/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Crizanlizumab for preventing sickle cell crises in sickle cell disease [TA743]	Recommended	03/11/2021	TA	01/02/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Upadacitinib for treating moderate rheumatoid arthritis [TA744]	Recommended	10/11/2021	TA	08/02/2022	CCG	24/11/2021	14	Upadacitinib is commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) [TA745]	Terminated appraisal	10/11/2021	TA					n/a	Link added to formulary
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer [TA746]	Recommended	17/11/2021	TA	15/02/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nintedanib for treating progressive fibrosing interstitial lung diseases [TA747]	Recommended	17/11/2021	TA	15/02/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders [TA748]	Recommended	01/12/2021	TA	01/03/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS Hospital trusts.	Link added to formulary
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) [TA749]	Not recommended	01/12/2021	TA					n/a	Link added to formulary
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) [TA750]	Terminated appraisal	08/12/2021	TA					n/a	Link added to formulary
Dupilumab for treating severe asthma with type 2 inflammation [TA751]	Recommended	08/12/2021	TA	08/03/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS Hospital trusts.	Link added to formulary
Belimumab for treating active autoantibody-positive systemic lupus erythematosus [TA752]	Recommended	15/12/2021	TA	15/03/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS Hospital trusts.	Link added to formulary
Cenobamate for treating focal onset seizures in epilepsy [TA753]	Recommended	15/12/2021	TA	15/03/2022	CCG	26/01/2022	42	Cenobamate is commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC amber initiated statement
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [TA754]	Recommended	15/12/2021	TA	15/03/2022	Non-CCG			Mogamulizumab is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Risdiplam for treating spinal muscular atrophy [TA755]	Recommended	16/12/2021	TA	16/03/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis [TA756]	Recommended	16/12/2021	TA	16/03/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Cabotegravir with rilpivirine for treating HIV-1 [TA757]	Recommended	05/01/2022	TA	05/04/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS Hospital trusts.	Link added to formulary
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [TA758]	Recommended	05/01/2022	TA	05/04/2022	CCG	26/01/2022	21	Solriamfetol is commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Fostamatinib for treating refractory chronic immune thrombocytopenia [TA759]	Not recommended	07/01/2022	TA					n/a	Pan Mersey APC black statement
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer [TA760]	Recommended	12/01/2022	TA	12/04/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF	Link added to formulary
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [TA761]	Recommended	19/01/2022	TA	19/04/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF	Link added to formulary
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) [TA762]	Not recommended	02/02/2022	TA					NICE is unable to make a recommendation on olaparib (Lynparza) for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy. This is because AstraZeneca did not provide an evidence submission. We will review this decision if the company decides to make a submission.	Link added to formulary
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable [TA763]	Recommended	02/02/2022	TA	03/05/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Fremanezumab for preventing migraine [TA764]	Recommended	02/02/2022	TA	03/05/2022	CCG	23/03/2022	49	Fremanezumab is commissioned by integrated care systems and clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement. Replaces TA631.
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [TA765]	Recommended	02/02/2022	TA	03/05/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma [TA766]	Recommended	02/02/2022	TA	03/05/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ponesimod for treating relapsing-remitting multiple sclerosis [TA767]	Recommended	02/02/2022	TA	03/05/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [TA768]	Recommended	02/02/2022	TA	03/05/2022	CCG	23/02/2022	21	Upadacitinib is commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement.
Palforzia for treating peanut allergy in children and young people [TA769]	Recommended	02/02/2022	TA	03/05/2022	CCG	23/02/2022	21	This technology is commissioned by clinical commissioning groups. It is expected to be provided in allergy clinics within NHS hospital trusts.	Pan Mersey APC red statement.
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer [TA770]	Recommended	09/02/2022	TA	03/05/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) [TA771]	Not recommended	09/02/2022	TA					NICE is unable to make a recommendation on daratumumab (Darzalex) with bortezomib, melphalan and prednisone for untreated multiple myeloma because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.	Link added to formulary
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies [TA772]	Recommended	23/02/2022	TA	10/05/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Empagliflozin for treating chronic heart failure with reduced ejection fraction [TA773]	Recommended	09/03/2022	TA	24/05/2022	CCG	27/04/2022	49	This technology is commissioned by integrated care systems groups and clinical commissioning groups. Providers are NHS hospital trusts and primary care providers.	Pan Mersey APC amber recommended statement
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) [TA774]	Not recommended	09/03/2022	TA					NICE is unable to make a recommendation on lenalidomide (Revlimid) for treating relapsed or refractory mantle cell lymphoma. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission.	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Dapagliflozin for treating chronic kidney disease [TA775]	Recommended	09/03/2022	TA	07/06/2022	CCG	23/03/2022	14	This technology is commissioned by integrated care systems/clinical commissioning groups. Providers are primary care services, NHS hospital trusts and tertiary care services.	Pan Mersey APC green statement
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [TA776]	Not recommended	09/03/2022	TA					N/A	Pan Mersey APC black statement
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [TA777]	Not recommended	09/03/2022	TA					N/A	Pan Mersey APC black statement
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [TA778]	Recommended	09/03/2022	TA	07/06/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA779]	Recommended	16/03/2022	TA	07/06/2022	Non-CCG			his technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma [TA780]	Recommended	24/03/2022	TA	14/06/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [TA781]	Recommended	30/03/2022	TA	22/06/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) [TA782]	Not recommended	30/03/2022	TA					N/A	Link added to formulary